165806-48-4

Basic information

• Product Name: 4-[4-(4-Fluorophenyl)-1-[3-(4-morpholinyl)propyl]-1H-imidazol-5-yl]pyrimidin-2-amine
• CAS NO: 165806-48-4
• Molecular Formula: C₂₀H₂₃FN₆O
• Molecular Weight: 382.44431
• Mol File: 165806-48-4.mol

Chemical Properties

• CAS DataBase Reference: 4-[4-(4-Fluorophenyl)-1-[3-(4-morpholinyl)propyl]-1H-imidazol-5-yl]pyrimidin-2-amine(CAS DataBase Reference)
• NIST Chemistry Reference: 4-[4-(4-Fluorophenyl)-1-[3-(4-morpholinyl)propyl]-1H-imidazol-5-yl]pyrimidin-2-amine(165806-48-4)
• EPA Substance Registry System: 4-[4-(4-Fluorophenyl)-1-[3-(4-morpholinyl)propyl]-1H-imidazol-5-yl]pyrimidin-2-amine(165806-48-4)

Safety Data

• Hazardous Substances Data: 165806-48-4(Hazardous Substances Data)

Upstream product

• 165806-95-1 1-((4-fluorophenyl)(isocyano)methylsulfonyl)-4-methylbenzene 
• 123-00-2 4-(3-Aminopropyl)morpholine 
• 67751-23-9 (E)-4-(dimethylamino)-1,1-dimethoxybut-3-en-2-one 
• 459-57-4 4-fluorobenzaldehyde 
• 77287-34-4 formamide 
• 165807-05-6 4-(dimethoxymethyl)pyrimidin-2-amine 
• 165807-06-7 2-Aminopyrimidine-4-carboxaldehyde 

Relevant articles and documents

Isonitrile intermediates for the preparation of tri-substituted imidazole compounds with multiple therapeutic properties

The invention relates to a novel group of isonitrile compounds and a process for their preparation, useful in the preparation of tri-substituted imadazoles having multiple therapeutic properties.

Imine intermediates for the preparation of trisubstituted imidazole compounds with multiple therapeutic properties

The invention relates to a novel group of iminc compounds and a process for their preparation, useful in the preparation of tri-substituted imadazoles having multiple therapeutic properties.

Formamide intermediates for the preparation of tri-substituted imidazole compounds with multiple therapeutic properties

The invention relates to a novel group of formamide compounds and a process for their preparation, useful in the preparation of tri-substituted imadazoles having multiple therapeutic properties.

Pyrimidinylimidazole inhibitors of CSBP/P38 kinase demonstrating decreased inhibition of hepatic cytochrome P450 enzymes

Pyrimidine analogs of the pyridinylimidazole class of CSBP/p38 kinase inhibitors were prepared in an effort to reduce the potent inhibition of hepatic cytochrome P450 observed for the pyridinyl compounds. The substitution of pyrimidin-4-yl, 2-methoxypyrimidin-4-yl, or 2- methylaminopyrimidin-4-yl for pyridin-4-yl effectively dissociates CSBP/p38 kinase from P450 inhibition for this series and furthermore achieves an increase in oral activity.

Imidazole compounds, use and process of making

Novel 1,4,5-substituted imidazole compounds and compositions for use in therapy as cytokine inhibitors.

Pyridyl imidazole compounds and compositions

Novel 1, 4, 5-substituted imidazole compounds and compositions for use in therapy as cytokine inhibitors.